Symptom Burden and Healthcare Resource Use in Claudin 18.2+ (CLDN18.2+), HER2− Patients With Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma

Speaker(s)

Sewastjanow da Silva M1, Rogers JE1, Waters RE1, Rosa Vicentini E1, Totev T2, Wu EQ2, Yang H2, Chang L3, Oh M4, Ajani J1
1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Analysis Group, Boston, MA, USA, 3Astellas Pharma, Inc., Northbrook, IL, USA, 4Astellas Pharma, Inc., Arlington Heights, IL, USA

Presentation Documents

OBJECTIVES: This retrospective study described the real-world symptoms of patients with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma and the healthcare resource utilization (HRU) in this population.

METHODS: Data were extracted from medical records from 2011–2022 of MD Anderson Cancer Center (MDACC) patients with CLDN18.2+, HER2−, LA/mG/GEJ adenocarcinoma. Corresponding tumor tissue samples were identified as positive for CLDN18.2 if ≥75% of tumor cells showed immunohistochemistry staining with antibody clone 43-14A. Outcomes were assessed from index date (date of diagnosis of LA/mG/GEJ adenocarcinoma) to end date (earliest of first-line treatment discontinuation, last follow-up visit, date of death, or 1 year after index date).

RESULTS: The patients meeting criteria (N=62; mean age, 61 years at index date; 55% male) mostly had gastric primary tumors (68%) and peritoneal metastases (76%). Nearly all patients (98%) received first-line treatment for advanced disease, with a mean of 37 days from initial diagnosis of LA/mG/GEJ adenocarcinoma to initiation of first-line treatment. On average, patients reported 7.2 symptoms at index date. The most common signs/symptoms at index date were weight loss (74%), abdominal/stomach pain (66%), anemia/weakness (61%), poor appetite (56%), and epigastric pain (50%). Close to three-quarters of patients (73%) had fewer symptoms at symptom collection end date; however, 16% developed at least 1 new symptom. During a mean follow-up from index date to end date of 6.5 months, patients had a mean of 3.4 MDACC visits per patient per month, 21% of patients had an inpatient admission (most commonly due to symptoms or a procedure/surgery; mean length of stay, 3.4 days per admission), and 35% had an emergency department visit (most commonly due to symptoms).

CONCLUSIONS: This analysis of patients with CLDN18.2+, HER2−, LA/mG/GEJ adenocarcinoma showed a substantial symptom burden and high HRU.

Code

SA30

Topic

Study Approaches

Topic Subcategory

Electronic Medical & Health Records

Disease

Gastrointestinal Disorders, No Additional Disease & Conditions/Specialized Treatment Areas